ES2524345T3 - Composición farmacéutica oral - Google Patents

Composición farmacéutica oral Download PDF

Info

Publication number
ES2524345T3
ES2524345T3 ES11169711.6T ES11169711T ES2524345T3 ES 2524345 T3 ES2524345 T3 ES 2524345T3 ES 11169711 T ES11169711 T ES 11169711T ES 2524345 T3 ES2524345 T3 ES 2524345T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
mini
colon
oral pharmaceutical
capsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11169711.6T
Other languages
English (en)
Spanish (es)
Inventor
Ivan Coulter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigmoid Pharma Ltd
Original Assignee
Sigmoid Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigmoid Pharma Ltd filed Critical Sigmoid Pharma Ltd
Application granted granted Critical
Publication of ES2524345T3 publication Critical patent/ES2524345T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
ES11169711.6T 2007-04-04 2008-04-04 Composición farmacéutica oral Active ES2524345T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90749007P 2007-04-04 2007-04-04
US907490P 2007-04-04
US649808P 2008-01-16 2008-01-16
US6498P 2008-01-16

Publications (1)

Publication Number Publication Date
ES2524345T3 true ES2524345T3 (es) 2014-12-05

Family

ID=39745242

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11169711.6T Active ES2524345T3 (es) 2007-04-04 2008-04-04 Composición farmacéutica oral
ES08719896T Active ES2400964T3 (es) 2007-04-04 2008-04-04 Composiciones famacéuticas de ciclosporina
ES08719898T Active ES2393814T3 (es) 2007-04-04 2008-04-04 Una composición farmacéutica oral

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES08719896T Active ES2400964T3 (es) 2007-04-04 2008-04-04 Composiciones famacéuticas de ciclosporina
ES08719898T Active ES2393814T3 (es) 2007-04-04 2008-04-04 Una composición farmacéutica oral

Country Status (11)

Country Link
US (11) US8911777B2 (enExample)
EP (5) EP2380564B1 (enExample)
JP (6) JP2010523555A (enExample)
CN (6) CN101677964A (enExample)
CA (3) CA2683409A1 (enExample)
CY (1) CY1113882T1 (enExample)
DK (1) DK2079456T3 (enExample)
ES (3) ES2524345T3 (enExample)
HR (1) HRP20130173T1 (enExample)
PT (1) PT2079456E (enExample)
WO (3) WO2008122966A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022195152A1 (es) * 2021-03-18 2022-09-22 Aora Health S.L. Sistema de administración en múltiples sitios para administración diferencial en el tracto gastrointestinal

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2922402B2 (ja) 1993-10-14 1999-07-26 住友重機械工業株式会社 熱成形方法及びその熱成形装置
EP2380564B1 (en) 2007-04-04 2014-10-22 Sigmoid Pharma Limited An oral pharmaceutical composition
JP2010527285A (ja) 2007-04-26 2010-08-12 シグモイド・ファーマ・リミテッド 複数のミニカプセルの製造
CA2685591A1 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
RS56049B1 (sr) * 2008-11-13 2017-09-29 Nogra Pharma Ltd Antisens kompozicije i postupci za pripremu i upotrebu istih
CN105213318A (zh) 2009-05-18 2016-01-06 希格默伊德药业有限公司 包含油滴的组合物
CN102573802A (zh) * 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
US20170079962A1 (en) 2009-11-11 2017-03-23 Rapamycin Holdings, Llc Oral Rapamycin Preparation and Use for Stomatitus
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
KR101245078B1 (ko) * 2010-11-11 2013-03-18 부산대학교 산학협력단 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
MX2021000431A (es) 2011-03-23 2022-10-28 Ironshore Pharmaceuticals & Dev Inc Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
CA2868990C (en) 2011-04-22 2018-08-14 Napo Pharmaceuticals, Inc. Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga)
CN103501812A (zh) 2011-04-29 2014-01-08 西莱克塔生物科技公司 用于过敏症治疗的致耐受性合成纳米载体
US9561241B1 (en) * 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
EP2817009A1 (en) * 2012-02-23 2014-12-31 INSERM - Institut National de la Santé et de la Recherche Médicale Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
CA3008794C (en) * 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
BR112014027496A2 (pt) * 2012-05-04 2018-05-15 Univ Chicago biodisponibilidade de metilnaltrexona oral aumenta com uma formulação à base de fosfatidilcolina
DE102012105528A1 (de) * 2012-06-25 2014-01-02 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur Freisetzung von Wirkstoffen
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
JP5992247B2 (ja) * 2012-08-13 2016-09-14 国立大学法人大阪大学 核酸医薬経口製剤
JP6062802B2 (ja) * 2012-08-23 2017-01-18 日清ファルマ株式会社 キトサン含有組成物及びキトサンコーティング組成物
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
EP2968329A4 (en) * 2013-03-15 2016-09-28 Galleon Pharmaceuticals Inc NEW BREATHING CONTROL MODULATION COMPOUNDS AND METHODS OF USING THE SAME
CA2910584A1 (en) 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells
US9415110B1 (en) 2013-05-08 2016-08-16 The Arizona Board of Regents on behalf of the Univeristy of Arizona Method and compositions for targeted drug delivery to the lower GI tract
CN104127466B (zh) * 2013-08-23 2018-05-22 江苏省中医药研究院 一种淫羊藿总黄酮口服肠溶制剂及其应用
CN104548063A (zh) * 2013-10-29 2015-04-29 中国科学院上海有机化学研究所 一种免疫抑制剂在制备线粒体丝氨酸/苏氨酸蛋白磷酸酶抑制剂中的用途
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
HUP1300647A2 (hu) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
EP3074028B1 (en) * 2013-11-27 2022-04-06 Research Foundation Of The City University Of New York Activity enhancing curcumin compositions and methods of use
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
GB201400442D0 (en) * 2014-01-10 2014-02-26 Sigmoid Pharma Ltd Compositions for use in the treatment of ulcerative colitis
EP3142645A4 (en) 2014-05-15 2017-12-27 Rani Therapeutics, LLC Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
JP6671360B2 (ja) * 2014-06-30 2020-03-25 サリックス ファーマスーティカルズ，インコーポレーテッド 過敏性腸症候群（ｉｂｓ）を再治療するための方法
EP3164145A4 (en) 2014-07-01 2018-01-17 Probi Usa, Inc. Bi-layer dual release probiotic tablets
AU2015299105B2 (en) * 2014-08-04 2020-10-29 Dbv Technologies Compositions of food allergens
WO2016034942A1 (en) 2014-09-02 2016-03-10 Purecircle Usa Inc. Stevia extracts enriched in rebaudioside d, e, n and/or o and process for the preparation thereof
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
CN104224732B (zh) * 2014-09-29 2017-06-30 江苏大学 一种口服骨架型环孢素a缓释微丸制剂及其制备方法
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
DK3215127T3 (da) * 2014-11-07 2021-02-01 Sublimity Therapeutics Ltd Sammensætninger omfattende cyclosporin
WO2016105498A1 (en) 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
CN104473907A (zh) * 2014-12-25 2015-04-01 北京华禧联合科技发展有限公司 一种他克莫司的口服缓释制剂
CN114949185A (zh) 2015-02-09 2022-08-30 安特拉贝欧有限公司 骨质疏松症的治疗
HK1250040A1 (zh) 2015-03-31 2018-11-23 Sorriso Pharmaceuticals, Inc. 多肽
CA2981098A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
CN113546036A (zh) 2015-05-01 2021-10-26 拉尼医疗有限公司 药物组合物和用于制备包含多肽和/或蛋白质的固体块的方法
US10286009B2 (en) * 2015-05-16 2019-05-14 Asterias Biotherapeutics, Inc. Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
EP3435982A1 (en) * 2016-03-31 2019-02-06 VHsquared Limited Compositions
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
TR201610597A2 (tr) * 2016-07-29 2016-12-21 Kamil Varlik Erel Mide ve bağırsak içine yerleştirilen tüp veya sondalardan kullanıma uygun ilaç
NZ751668A (en) * 2016-08-17 2022-07-29 Entera Bio Ltd Formulations for oral administration of active agents
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CA3046023A1 (en) * 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
JP7150723B2 (ja) * 2016-12-14 2022-10-11 ビオラ・セラピューティクス・インコーポレイテッド 消化管疾病のインテグリン阻害薬による治療
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018112232A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
US12102721B2 (en) 2017-01-26 2024-10-01 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
EP3592389B1 (en) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US11596670B2 (en) 2017-03-30 2023-03-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
WO2018183934A1 (en) * 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
US20210138213A1 (en) * 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018231619A1 (en) * 2017-06-14 2018-12-20 SpecGx LLC Delayed sustained release pharmaceutical compositions
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
CN111225686A (zh) * 2017-08-15 2020-06-02 普罗根尼蒂公司 使用可摄入装置释放免疫调节剂治疗炎性疾病
EP3459527B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
AU2018345812A1 (en) * 2017-10-05 2020-05-14 Spoke Sciences, Inc. Herbal compositions with improved bioavailability
AU2018351502B2 (en) * 2017-10-20 2024-09-05 Purdue Pharma L.P. Pharmaceutical dosage forms
CA3085330A1 (en) * 2017-12-14 2019-06-20 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a s1p modulator
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
CN108379238B (zh) * 2018-01-17 2020-07-14 南昌大学 一种储存物理稳定性好的环孢素固体脂质纳米粒及其制备方法
US12005086B2 (en) 2018-02-23 2024-06-11 Finch Therapeutics Holdings Llc Microbiome related immunotherapies
AU2019232145B2 (en) * 2018-03-07 2024-08-08 Teagasc - The Agriculture And Food Development Authority A composition for type II diabetics and for use in providing sustained energy release over time
US10835489B2 (en) 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
WO2019183109A1 (en) * 2018-03-19 2019-09-26 Gemini Laboratories, Llc Immunosuppressive dosage forms and methods of use
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
WO2020106330A1 (en) * 2018-07-18 2020-05-28 Pillsy, Inc. Smart drug delivery and monitoring device, kit, and method of use for pill compounds
EP4438618A3 (en) 2018-08-22 2025-01-01 Bacainn Biotherapeutics, Ltd. Cyclosporine compositions and methods of use
US12365872B2 (en) 2018-09-19 2025-07-22 Lineage Cell Therapeutics, Inc. Methods for differentiating pluripotent stem cells in dynamic suspension culture
CN110934831B (zh) * 2018-09-25 2021-09-14 天津大学 二甲基乙二酰甘氨酸-白藜芦醇核壳型纳米材料及其制备方法
US11839605B2 (en) * 2018-10-11 2023-12-12 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP3934677A4 (en) 2019-03-13 2022-11-16 University of Virginia Patent Foundation COMPOSITIONS AND METHODS TO PROMOTE ISLAND VIABILITY AND INCREASE INSULINE SECRETION
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
EP3986931A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
AU2020294980A1 (en) 2019-06-21 2022-02-17 Sorriso Pharmaceuticals, Inc. Polypeptides
EP4588511A3 (en) 2019-07-18 2025-07-30 Theriva Biologics, Inc. Intestinal alkaline phosphatase-based treatments of metabolic disorders
PE20221399A1 (es) 2019-07-19 2022-09-15 Finch Therapeutics Holdings Llc Metodos y productos para el tratamiento de trastornos gastrointestinales
WO2021030474A1 (en) 2019-08-12 2021-02-18 Massachusetts Institute Of Technology Articles and methods for administration of therapeutic agents
WO2021034727A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
US20220331378A1 (en) 2019-09-13 2022-10-20 Finch Therapeutics Holdings Llc Compositions and methods for treating autism spectrum disorder
CN115279382A (zh) 2019-10-18 2022-11-01 芬奇治疗控股有限责任公司 用于向受试者递送细菌代谢物的组合物和方法
WO2021097288A1 (en) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions and methods for treating neurodegenerative diseases
CN111297953A (zh) * 2019-12-20 2020-06-19 卓和药业集团有限公司 一种预防肾脏移植后移植排斥反应的复方制剂
WO2021142358A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatic encephalopathy (he)
WO2021142347A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for non-alcoholic steatohepatitis (nash)
WO2021142353A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv)
US20230149295A1 (en) * 2020-03-09 2023-05-18 University Of Houston System Inflammatory bowel disease stem cells, agents which target ibd stem cells, and uses related thereto
US20230201265A1 (en) 2020-03-31 2023-06-29 Finch Therapeutics Holdings Llc Compositions comprising non-viable fecal microbiota and methods of use thereof
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent
AU2021377219A1 (en) 2020-11-10 2023-06-29 Medregen, Llc Formulations, methods, kits, and dosage forms
KR20230127239A (ko) * 2020-11-30 2023-08-31 로얄 멜버른 인스티튜트 오브 테크놀로지 경구 치료 전달
US20240263251A1 (en) 2021-02-19 2024-08-08 Finch Therapeutics Holdings Llc Compositions and methods for providing secondary bile acids to a subject
AU2022345789A1 (en) * 2021-09-14 2024-03-28 Nulixir Inc. Alimentary-related particles, production methods, and production apparatus
KR102874663B1 (ko) * 2021-12-22 2025-10-23 알고케어 주식회사 구 형상의 제형을 제공하는 디스펜서
CN114916591A (zh) * 2022-06-09 2022-08-19 江西维尔宝食品生物有限公司 一种起酥性烘焙专用可塑性粉末油脂组合物
US11806430B1 (en) 2023-02-24 2023-11-07 King Faisal University Rectal gel with date palm phenolics and vanillic acid
AU2024252387A1 (en) * 2023-04-14 2025-10-02 Vitakey Inc. Compositions and methods of controlling mammalian satiety
CN116650444B (zh) * 2023-07-31 2023-10-31 国药集团川抗制药有限公司 一种他克莫司缓释药物及其制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3971852A (en) 1973-06-12 1976-07-27 Polak's Frutal Works, Inc. Process of encapsulating an oil and product produced thereby
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IT1090703B (it) 1976-12-03 1985-06-26 Scherer Ltd R P Perfezionamento nelle composizioni utili quali veicolo per farmaci
FI65914C (fi) 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
US4279632A (en) * 1979-05-08 1981-07-21 Nasa Method and apparatus for producing concentric hollow spheres
IT1148784B (it) 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
JPS6415Y2 (enExample) 1981-05-29 1989-01-05
DE3224619A1 (de) * 1981-07-14 1983-05-19 Freund Industrial Co., Ltd., Tokyo Orale pharmazeutische zusammensetzung
JPS5813508A (ja) 1981-07-14 1983-01-26 Taiho Yakuhin Kogyo Kk ポリグリセロール飽和脂肪酸エステルを含む経口薬剤組成物
JPS5877810A (ja) 1981-11-01 1983-05-11 Taiho Yakuhin Kogyo Kk ポリグリセロ−ル不飽和脂肪酸エステルを含む経口薬剤組成物
US4481157A (en) * 1982-04-27 1984-11-06 Morishita Jintan Co., Ltd. Method and apparatus for production of microcapsules
US4597959A (en) 1982-04-30 1986-07-01 Arthur Barr Sustained release breath freshener, mouth and palate coolant wafer composition and method of use
US4422985A (en) * 1982-09-24 1983-12-27 Morishita Jintan Co., Ltd. Method and apparatus for encapsulation of a liquid or meltable solid material
JPS5988420A (ja) 1982-11-12 1984-05-22 Teisan Seiyaku Kk シ−ムレスカプセル化ニフエジピン製剤
JPS5988420U (ja) 1982-12-04 1984-06-15 有限会社三和ボタン店 学生服の詰襟構造
JPS59131355A (ja) * 1983-01-17 1984-07-28 森下仁丹株式会社 多重軟カプセルの製法
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPS6115A (ja) 1984-06-12 1986-01-06 Kyowa Hakko Kogyo Co Ltd リポキシゲナ−ゼ代謝産物に起因する疾患の予防治療剤
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS61115462A (ja) 1984-11-13 1986-06-03 Denka Seiyaku Kk 甘味増強ステビア葉の製法
JPS61151119A (ja) 1984-12-24 1986-07-09 Taisho Pharmaceut Co Ltd ソフトカプセル
US4601894A (en) 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4658441A (en) * 1985-12-13 1987-04-21 Smith Steven A One piece thumb support and protector
EP0241806A1 (en) * 1986-04-14 1987-10-21 Fujisawa Pharmaceutical Co., Ltd. Sustained-release transdermal delivery preparations
US4857335A (en) * 1987-03-27 1989-08-15 Lim Technology Laboratories, Inc. Liquid controlled release formulations and method of producing same via multiple emulsion process
US4891223A (en) 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
ATE109970T1 (de) * 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
JPS6415A (en) 1988-03-17 1989-01-05 Freunt Ind Co Ltd Absorption-improving drug preparation
US4910191A (en) * 1988-06-28 1990-03-20 Merrell Dow Pharmaceuticals Inc. 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
WO1990006775A1 (en) 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JP2806564B2 (ja) * 1989-07-20 1998-09-30 森下仁丹株式会社 親水性物質を内容物とするシームレスカプセルおよびその製法
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5260071A (en) * 1989-12-18 1993-11-09 Lemelson Jerome H Drug units and methods for using same
BE1003677A3 (nl) 1990-01-29 1992-05-19 Schacht Etienne Werkwijze voor het bereiden van azobevattende polymeren en het gebruik ervan als geneesmiddelafgiftesystemen.
IL98087A (en) 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
ATE103806T1 (de) * 1990-07-04 1994-04-15 Shionogi & Co Verfahren zur herstellung einer nichtkohaesiven ueberzugsschicht.
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5418010A (en) * 1990-10-05 1995-05-23 Griffith Laboratories Worldwide, Inc. Microencapsulation process
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
SG48815A1 (en) 1991-06-28 1998-05-18 Univ Brown Res Found Capsule extrusion systems
JP3313124B2 (ja) 1991-07-31 2002-08-12 森下仁丹株式会社 親水性物質を内容物とするシームレスカプセルおよびその製法
JPH0549899A (ja) 1991-08-09 1993-03-02 Japan Tobacco Inc ビーズ及びこれを製造するための液滴生成装置
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU666895B2 (en) 1991-12-30 1996-02-29 Hercules Incorporated High load spray dry encapsulation
AU3343093A (en) 1992-01-17 1993-08-03 Alfatec-Pharma Gmbh Pellets containing peptide drugs, their manufacture and use
DE4201179A1 (de) 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
US5571533A (en) 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
EP0573978B1 (en) * 1992-06-12 1999-04-21 Kao Corporation Bath additive composition comprising surfactant-containing seamless capsules and method for producing the capsules.
JP3405746B2 (ja) * 1992-10-28 2003-05-12 フロイント産業株式会社 シームレスカプセルの製造方法
DE69332031T2 (de) 1993-01-08 2002-12-19 Csl Ltd., Parkville Impfstoffpräparate
GB9300875D0 (en) * 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5843347A (en) * 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
CN1077800C (zh) * 1993-07-01 2002-01-16 韩美药品工业株式会社 环孢菌素软胶囊组合物
FR2707184B1 (fr) * 1993-07-08 1995-08-11 Rhone Poulenc Nutrition Animal Procédé de préparation de sphérules contenant un principe actif alimentaire ou pharmaceutique.
DE4329503A1 (de) 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
US6204243B1 (en) * 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
DE4332041C2 (de) 1993-09-21 1997-12-11 Rentschler Arzneimittel Verwendung von Pentoxifyllin bei bestimmten Lungenerkrankungen
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995022343A1 (en) 1994-02-17 1995-08-24 Shiseido Company, Ltd. Cyclosporin-containing emulsion composition
US5498439A (en) 1994-03-04 1996-03-12 Arnhem, Inc. Process for encapsulating the flavor with colloid gel matrix
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JP3867171B2 (ja) 1994-04-22 2007-01-10 アステラス製薬株式会社 結腸特異的薬物放出システム
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
FR2721510B1 (fr) 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticules filtrables dans des conditions stériles.
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE4430127A1 (de) * 1994-08-25 1996-03-14 Hoechst Ag Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
US5650232A (en) 1994-10-07 1997-07-22 Warner-Lambert Company Method for making seamless capsules
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5827531A (en) * 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
US5529783A (en) * 1994-12-19 1996-06-25 Mcneil-Ppc, Inc. Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
KR0167613B1 (ko) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5674495A (en) * 1995-02-27 1997-10-07 Purdue Research Foundation Alginate-based vaccine compositions
US5595757A (en) 1995-03-29 1997-01-21 Warner-Lambert Company Seamless capsules
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5767153A (en) 1995-06-07 1998-06-16 Insite Vision Incorporated Sustained release emulsions
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
SE504582C2 (sv) 1995-07-06 1997-03-10 Gs Dev Ab Cyklosporinkomposition baserad på en L2-fas
JP2682818B2 (ja) 1995-08-04 1997-11-26 大成化工株式会社 害虫誘引阻止材
ATE263550T1 (de) 1995-08-25 2004-04-15 Sangstat Medical Corp Orale cyclosporinformulierungen
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
JP3759986B2 (ja) * 1995-12-07 2006-03-29 フロイント産業株式会社 シームレスカプセルおよびその製造方法
DK0876142T3 (da) 1996-01-16 2001-11-19 Advanced Polymer Systems Inc Topisk tilførsel af lægemidler til den nedre mavetarmkanal
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US5686133A (en) 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
KR0183449B1 (ko) * 1996-06-19 1999-05-01 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제
US5958876A (en) 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
ES2565163T3 (es) 1996-10-28 2016-03-31 General Mills, Inc. Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
CA2283780A1 (en) 1997-03-12 1998-09-17 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
DZ2479A1 (fr) 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
CA2288876A1 (en) 1997-05-06 1998-11-12 Xiao Yu Wu Drug delivery system
JP4102459B2 (ja) * 1997-05-14 2008-06-18 森下仁丹株式会社 生体高分子を合成するシームレスカプセルおよびその製造方法
SE9702533D0 (sv) * 1997-07-01 1997-07-01 Astra Ab New oral formulation
PT999826E (pt) 1997-07-29 2004-09-30 Upjohn Co Formulacao auto-emulsionante para compostos lipofilos
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
JP3090198B2 (ja) 1997-08-21 2000-09-18 日本電気株式会社 半導体装置の構造およびその製造方法
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
KR100569319B1 (ko) 1997-10-30 2006-04-07 모리시타 진탄 가부시키가이샤 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법
US5891845A (en) 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
IT1296585B1 (it) 1997-11-28 1999-07-14 Uni Di Pavia Microcapsule contenenti materiale seminale per l'inseminazione strumentale nella specie suina
US6509346B2 (en) * 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US20040062802A1 (en) * 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
US6174466B1 (en) * 1998-05-08 2001-01-16 Warner-Lambert Company Methods for making seamless capsules
DE19821951A1 (de) * 1998-05-15 1999-11-18 Basf Ag Cyclosporin-Zubereitungen
JPH11322587A (ja) * 1998-05-18 1999-11-24 Sumitomo Chem Co Ltd 常温で固体の生理活性物質のマイクロカプセル化方法およびこの方法により得られるマイクロカプセル組成物
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
MXPA01003197A (es) 1998-09-28 2004-04-21 Warner Lambert Co Suministro enterico y colonico utilizando capsulas de chpm.
DE19848849A1 (de) 1998-10-22 2000-04-27 Knoll Ag Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz
US6638522B1 (en) 1998-12-11 2003-10-28 Pharmasolutions, Inc. Microemulsion concentrate composition of cyclosporin
JP3039863B1 (ja) * 1998-12-25 2000-05-08 不二精工株式会社 ロッキングプレス装置
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
JP2000247911A (ja) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc 大腸用吸収促進剤
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
JP2000302654A (ja) 1999-04-16 2000-10-31 Kao Corp 歯磨組成物の製造法
US8663692B1 (en) 1999-05-07 2014-03-04 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
WO2000069420A1 (en) 1999-05-14 2000-11-23 Coraltis Ltd. Pulse-delivery oral compositions
EP1184038B1 (en) 1999-06-09 2005-12-28 Mochida Pharmaceutical Co., Ltd. System for release in lower digestive tract
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030235595A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CA2391707C (en) 1999-07-30 2010-05-11 Smithkline Beecham Plc Multi-component pharmaceutical dosage form
WO2001032142A1 (en) 1999-11-02 2001-05-10 Cipla Limited Cyclosporin formulation
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2004504264A (ja) * 2000-01-07 2004-02-12 ユニバーシティ　オブ　シンシナティ Ｔｈ１又はｔｈ２リンパ球に制御される免疫応答の選択的活性化
AU2001257359A1 (en) 2000-04-27 2001-11-07 Verion Inc. Zero order release and temperature-controlled microcapsules and process for the preparation thereof
DE60112073T2 (de) 2000-05-12 2006-04-20 Pharmacia & Upjohn Co. Llc, Kalamazoo Impfstoffzusammensetzung und verfahren zur herstellung derselben sowie verfahren zur impfung von wirbeltieren
GB0018527D0 (en) 2000-07-27 2000-09-13 Photocure Asa Composition
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
CA2441007C (en) 2001-03-15 2009-06-09 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20030083286A1 (en) 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
FR2830447B1 (fr) 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US6951655B2 (en) * 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
WO2003053404A1 (en) 2001-12-20 2003-07-03 Bernard Charles Sherman Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
DE60213471T2 (de) 2002-01-10 2007-08-23 Firmenich S.A. Prozess zur herstellung extrudierter abgabesysteme
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
US20030207907A1 (en) 2002-05-03 2003-11-06 Iversen Patrick L. Delivery of microparticle-conjugated drugs for inhibition of stenosis
JP4226846B2 (ja) * 2002-06-07 2009-02-18 キャタレント・ジャパン株式会社 口腔内で崩壊可能なソフトカプセル剤
GB2391473B (en) 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
GB2408729A (en) 2002-09-04 2005-06-08 Southwest Res Inst Microencapsulation of oxygen or water sensitive materials
KR20120038546A (ko) 2002-11-01 2012-04-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
WO2004064997A1 (en) 2003-01-23 2004-08-05 Inotech Ag New microcapsules useful as extraction means in particular for extracting water or soil contaminants
WO2004073551A2 (en) 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
EP2359817B1 (en) 2003-03-28 2018-01-10 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
CA2521051C (en) * 2003-04-04 2012-03-20 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
BRPI0414000B8 (pt) 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
ES2373937T3 (es) * 2003-11-21 2012-02-10 Commonwealth Scientific And Industrial Research Organisation Sistemas gastro-intestinales de administración.
WO2005072088A2 (en) 2003-12-11 2005-08-11 Sciperio, Inc. Immunotherapy compositions, method of making and method of use thereof
CN1268325C (zh) 2004-01-18 2006-08-09 浙江大学 三重复合微球制剂及其制备方法
AU2005210668A1 (en) 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
AR048033A1 (es) * 2004-03-12 2006-03-22 Smithkline Beecham Plc Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion
FR2867395B1 (fr) 2004-03-15 2006-06-16 Rhodia Chimie Sa Emulsion sechee, son procede de preparation, et ses utilisations
EP1576881A1 (en) * 2004-03-15 2005-09-21 Urea Casale S.A. Process for the production of granules or pellets containing filamentary fungi
DK1746980T3 (da) 2004-05-07 2012-01-30 Nycomed Gmbh Farmaceutisk doseringsform omfattende pellets såvel som deres fremstillingsfremgangsmåde
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
WO2006002365A2 (en) 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
GB0417481D0 (en) * 2004-08-05 2004-09-08 Etiologics Ltd Combination therapy
WO2006026592A2 (en) 2004-08-27 2006-03-09 Spherics, Inc. Oral administration of poorly absorbed drugs, methods and compositions related thereto
US7718624B2 (en) * 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
US20060135441A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors
DE602005010899D1 (de) * 2004-09-27 2008-12-18 Sigmoid Pharma Ltd Mikrokapseln mit einem methylxanthin und einem kortikosteroid
IE20050639A1 (en) * 2004-09-27 2006-09-06 Sigmoid Biotechnologies Ltd Minicapsule formulations
FI20041425A0 (fi) * 2004-11-05 2004-11-05 Orion Corp Transmukosaalinen veterinäärinen koostumus
CN101212953A (zh) * 2005-03-29 2008-07-02 麦克内尔-Ppc股份有限公司 具有疏水介质中的亲水药物的组合物
US7825087B2 (en) 2005-04-12 2010-11-02 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
TW200800305A (en) 2005-07-26 2008-01-01 Glaxo Group Ltd Encapsulation of lipid-based formulations in enteric polymers
WO2007014445A1 (en) 2005-08-02 2007-02-08 Miv Therapeutics Inc. Microdevices comprising nanocapsules for controlled delivery of drugs and method of manufacturing same
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
BRPI0707616A2 (pt) 2006-02-09 2011-05-10 Alba Therapuetics Corp formulaÇÕes para um efetor de junÇço oclusiva
US20070274932A1 (en) * 2006-05-15 2007-11-29 The Procter & Gamble Company Water in oil emulsion compositions containing sunscreen actives and siloxane elastomers
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US20080124279A1 (en) * 2006-11-17 2008-05-29 Antoine Andremont Colonic delivery using Zn/pectin beads with a Eudragit coating
EP2380564B1 (en) 2007-04-04 2014-10-22 Sigmoid Pharma Limited An oral pharmaceutical composition
CA2685591A1 (en) 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
WO2009002533A1 (en) 2007-06-27 2008-12-31 The Brigham And Women's Hospital, Inc. Inflammatory bowel disease therapies
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022195152A1 (es) * 2021-03-18 2022-09-22 Aora Health S.L. Sistema de administración en múltiples sitios para administración diferencial en el tracto gastrointestinal
ES2924573A1 (es) * 2021-03-18 2022-10-07 Aora Health S L Sistema de administracion en multiples sitios para administracion diferencial en el tracto gastrointestinal

Also Published As

Publication number Publication date
CN101686948B (zh) 2013-06-19
DK2079456T3 (da) 2013-03-18
CN103316326A (zh) 2013-09-25
WO2008122966A2 (en) 2008-10-16
HRP20130173T1 (hr) 2013-04-30
WO2008122967A3 (en) 2008-12-24
CN103120653A (zh) 2013-05-29
EP2066309B1 (en) 2012-08-29
JP2010523554A (ja) 2010-07-15
US20160166635A1 (en) 2016-06-16
CA2683409A1 (en) 2008-10-16
JP2016074686A (ja) 2016-05-12
EP2079456B1 (en) 2012-12-05
JP2017160241A (ja) 2017-09-14
CA2683415C (en) 2020-12-08
US10434139B2 (en) 2019-10-08
EP2409691A1 (en) 2012-01-25
EP2066309A2 (en) 2009-06-10
US10434140B2 (en) 2019-10-08
US9585844B2 (en) 2017-03-07
US20200009218A1 (en) 2020-01-09
US9675558B2 (en) 2017-06-13
CA2683415A1 (en) 2008-10-16
EP2380564A3 (en) 2012-11-14
US20170246242A1 (en) 2017-08-31
CN103316326B (zh) 2016-06-15
WO2008122965A2 (en) 2008-10-16
EP2079456A2 (en) 2009-07-22
EP2380564B1 (en) 2014-10-22
US20170196934A1 (en) 2017-07-13
WO2008122965A3 (en) 2008-12-24
CN103120653B (zh) 2015-09-30
CA2683407C (en) 2016-09-20
US20150374638A1 (en) 2015-12-31
CN105030729A (zh) 2015-11-11
US8911777B2 (en) 2014-12-16
EP2061440A2 (en) 2009-05-27
JP6149090B2 (ja) 2017-06-14
US20130330411A1 (en) 2013-12-12
US20100297221A1 (en) 2010-11-25
CN101686948A (zh) 2010-03-31
ES2400964T3 (es) 2013-04-15
US20200009219A1 (en) 2020-01-09
EP2380564A2 (en) 2011-10-26
CY1113882T1 (el) 2016-07-27
US9387179B2 (en) 2016-07-12
JP2014196368A (ja) 2014-10-16
ES2393814T3 (es) 2012-12-28
US20120258167A1 (en) 2012-10-11
US8535713B2 (en) 2013-09-17
JP6059688B2 (ja) 2017-01-11
US9844513B2 (en) 2017-12-19
US9114071B2 (en) 2015-08-25
WO2008122966A3 (en) 2008-12-24
PT2079456E (pt) 2013-03-13
JP5553747B2 (ja) 2014-07-16
US20100203120A1 (en) 2010-08-12
CA2683407A1 (en) 2008-10-16
WO2008122967A2 (en) 2008-10-16
US20100255087A1 (en) 2010-10-07
CN101677964A (zh) 2010-03-24
CN101990429A (zh) 2011-03-23
JP2010523555A (ja) 2010-07-15
JP2010523553A (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
ES2524345T3 (es) Composición farmacéutica oral
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2582779T3 (es) Forma de dosificación oral de acetaminofeno/tramadol de liberación prolongada
CU20080052A7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
BRPI0810390A2 (pt) Película, composição, e, métodos para administrar um material ativo, para melhorar a estabilidade de uma película e para manter a saúde sistêmica de um mamífero
EP2493457A4 (en) FAST SOLUBLE SOLID DOSAGE FORM
CL2007001902A1 (es) Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas.
CL2009002073A1 (es) Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.
CL2008001821A1 (es) Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
FR2934156B1 (fr) Medicament appetissant a administration orale sous forme solide
CR20110110A (es) Composicion farmaceutica
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
ES2662320T3 (es) Sistema de matriz autoadhesiva que comprende un copolímero de bloques de estireno
AR082493A1 (es) Formulaciones a base de nalbufina, y sus utilizaciones
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
AR063027A1 (es) Derivados de sulfonamida
ECSP088722A (es) Formulaciones medicamentosas que contienen fluoroquinolonas
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
DE602007011316D1 (de) Pharmazeutische zusammensetzung mit antipsychotischer, antidepressiver oder antiepileptischer wirkung mit verringerter nebenwirkung
AR064104A1 (es) Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas